Black Diamond Therapeutics Inc. (BDTX) News
Filter BDTX News Items
BDTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BDTX News Highlights
- BDTX's 30 day story count now stands at 2.
- Over the past 8 days, the trend for BDTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest BDTX News From Around the Web
Below are the latest news stories about BLACK DIAMOND THERAPEUTICS INC that investors may wish to consider to help them evaluate BDTX as an investment opportunity.
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBMInitial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months 19 patients with measurable disease by RANO criteria: 1 patient with confirmed partial response and 8 patients with stable disease BDTX-1535 generally well tolerated, consistent with prior disclosures and no new safety signals observed “Window of opportunity” trial enrol |
With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backingKey Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to... |
Black Diamond Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences: The Stifel 2023 Healthcare Conference at 2:25pm ET on Tuesda |
Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate UpdateCompany's cash position stands at $144.3 million, sufficient to fund operations into H1 2025 |
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePresented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor |
Black Diamond Therapeutics Insider Ups Holding By 82% During YearFrom what we can see, insiders were net buyers in Black Diamond Therapeutics, Inc.'s ( NASDAQ:BDTX ) during the past 12... |
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200mg and 300mg Initial NSCLC expansion cohort data expected in 2024 Initial GBM dose escalation data expected later this year CAMBRIDGE, Mass. and NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology |
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsCAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalatio |
Co-founder of cancer biotech Black Diamond replaced as CEOThe board of Black Diamond Therapeutics has replaced its CEO, David Epstein, a Brandeis-trained biochemist. |
Black Diamond Therapeutics Announces CEO TransitionCurrent Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately. Dr. |